Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.61 Analyst target: $15.21 Upside: 321.33%
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.